Author:
FAQ: Using Plateable Hepatocytes in In Vitro Assays
Plateable hepatocytes are often used for induction studies and to research metabolism, biochemistry, virology, host/pathogen interactions, and cell biology. Here,...
Ask Me Anything About In Vitro ADME, Drug-Drug Interaction Approaches and Strategies
Last month, Dr. Joanna Barbara joined AAPS for an online Q&A in their ongoing “Ask the Experts” series. As regulatory...
Are in vitro drug metabolism and drug-drug interaction studies critical for an IND?
A Guide to What, Why & When to Conduct ADME Studies When drug developers are preparing their IND, drug metabolism...
4 Ways De-Risking Maximizes Compound Value
Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early in...
New FDA Draft Guidance “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics” – XenoTech’s perspective on in vitro DDI testing
The FDA has released a new draft guidance for industry titled “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics.”...
Spotlight on Efflux and Uptake Drug Transporters in In Vitro Drug-Drug Interaction Studies
What are drug transporters? Drug transporters are membrane-bound proteins that assist in the movement of drugs into or out of...
When, Why and How to Conduct CYP2C Induction Studies
Over the years, we have received a lot of questions about cytochrome P450 (CYP) 2C induction studies. In February of...
Which Hepatocytes Should I Use for What Studies?
Primary hepatocytes are considered the gold standard for ADME/DMPK studies because they are the most representative in vitro test system. However, not all hepatocyte formats…
Meet the Scientist: Alex Wakefield
In this month’s installment of our Meet the Scientist series we wanted to feature one of our team of talented...
Why Do Most Polled Researchers Run Red Blood Cell Partitioning Studies with Plasma Protein Binding?
Many compounds bind to or diffuse into red blood cells (RBCs), which can significantly impact clearance and cause inaccuracies in PK calculations...
Highlights from the 2021 Marbach Drug-Drug Interaction Workshop
Reflecting on the virtual conferences in 2021, I would like to look back at some of the highlights from the...
2021 Service Expansions: Microsomal Protein Binding and Red Blood Cell Partitioning
Over the course of 2021, we expanded access to two important and related study offerings at our US laboratory headquarters....
Notes from the 2021 HRA Expert Panel Discussion “Are Standard Hepatocyte Models/Test Systems Still Good Enough?”
MicroPhysiological Systems (MPS) is a general term used to describe miniaturized, in vitro test systems that couple microfluidics with advanced...
Meet the Scientists: Program Execution
In this installment of our Meet the Scientist series, we asked several members from various areas of our Program Execution...
Interesting Topics at the 3rd SCI-RSC Symposium on Transporters in Drug Discovery and Development
A recap of some of the important and promising research that was presented at the Transporters in Drug Discovery and Development symposium...
Meet the Scientists: Analytical Services’ Chandra Kollu & Nadya Galeva
This month we’re featuring two of the experts in our analytical services department: Senior Scientist Chandra Kollu and Mass Spectrometry...
ADME/PK & DDI Best Practices Industry Survey Results & Infographic
With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these studies...
Guide to When & Why to Evaluate ADME/DMPK & Drug-Drug Interactions Available
In Safety first: Assessing drugs early can preclude regulatory and health issues, a new ebook developed by a collaboration with...